{"organizations": [], "uuid": "9dbff3548d9349822b44e853925d0863c2022382", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-lycera-corp-announces-initiation-o/brief-lycera-corp-announces-initiation-of-phase-1b-study-of-novel-immuno-oncology-candidate-lyc-55716-in-combination-with-pembrolizumab-idUSFWN1OZ0NB", "country": "US", "domain_rank": 408, "title": "BRIEF-Lycera Corp Announces Initiation Of Phase 1b Study Of Novel Immuno-Oncology Candidate LYC-55716 In Combination With Pembrolizumab", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T15:47:00.000+02:00", "replies_count": 0, "uuid": "9dbff3548d9349822b44e853925d0863c2022382"}, "author": "", "url": "https://www.reuters.com/article/brief-lycera-corp-announces-initiation-o/brief-lycera-corp-announces-initiation-of-phase-1b-study-of-novel-immuno-oncology-candidate-lyc-55716-in-combination-with-pembrolizumab-idUSFWN1OZ0NB", "ord_in_thread": 0, "title": "BRIEF-Lycera Corp Announces Initiation Of Phase 1b Study Of Novel Immuno-Oncology Candidate LYC-55716 In Combination With Pembrolizumab", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-lycera corp", "sentiment": "negative"}, {"name": "reuters) - merck & co inc", "sentiment": "none"}, {"name": "pembrolizumab reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 1:49 PM / Updated 8 minutes ago BRIEF-Lycera Corp Announces Initiation Of Phase 1b Study Of Novel Immuno-Oncology Candidate LYC-55716 In Combination With Pembrolizumab Reuters Staff 1 Min Read \nJan 4 (Reuters) - Merck & Co Inc: \n* LYCERA CORP ANNOUNCES INITIATION OF PHASE 1B STUDY OF NOVEL IMMUNO-ONCOLOGY CANDIDATE LYC-55716 IN COMBINATION WITH PEMBROLIZUMAB Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T15:47:00.000+02:00", "crawled": "2018-01-04T16:11:46.007+02:00", "highlightTitle": ""}